BGI Genomics controversies

BGI Group prenatal genetic testing raises data privacy and cross-border regulatory concerns

In 2021, Reuters reported on genetic data research from BGI Group's NIFTY prenatal test and cooperation with military hospitals, triggering reviews by regulators in multiple countries. BGI denied the claim that it jointly developed the test with the military, saying it complies with privacy laws and has not been asked to provide data for national security purposes. This entry concerns controversy over the group's associated testing business, not a conviction that the listed company stole data.

BGI Genomics responds to concerns about COVID-19 test kits

Company response

In August 2020, BGI Genomics responded to media concerns regarding a high positive detection rate associated with its COVID-19 test kits. The company stated that the high sensitivity of the tests could produce positive results, and that this characteristic could be useful for epidemic prevention among the general population. The response addressed questions raised in media reports about the positive detection rate of the kits.

BGI Genomics responded to media concerns about a high positive detection rate for its COVID-19 test kits, stating that the high sensitivity of the tests could produce positive results and could be useful for epidemic prevention among the general population.